CN103124788B - 双特异性融合蛋白 - Google Patents

双特异性融合蛋白 Download PDF

Info

Publication number
CN103124788B
CN103124788B CN201180035656.1A CN201180035656A CN103124788B CN 103124788 B CN103124788 B CN 103124788B CN 201180035656 A CN201180035656 A CN 201180035656A CN 103124788 B CN103124788 B CN 103124788B
Authority
CN
China
Prior art keywords
fusion protein
seq
mhsa
bispecific fusion
tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201180035656.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN103124788A (zh
Inventor
U·尼尔森
T·威克汉姆
B·舍贝尔
B·哈姆斯
B·林吉
M·昂桑姆
B·德拉巴瑞
S·M·利珀
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Silver Brook Pharmaceutical Ltd By Share Ltd
Original Assignee
Merrimack Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrimack Pharmaceuticals Inc filed Critical Merrimack Pharmaceuticals Inc
Priority to CN201510960252.3A priority Critical patent/CN105524176B/zh
Publication of CN103124788A publication Critical patent/CN103124788A/zh
Application granted granted Critical
Publication of CN103124788B publication Critical patent/CN103124788B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Nanotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
CN201180035656.1A 2010-05-21 2011-05-20 双特异性融合蛋白 Active CN103124788B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510960252.3A CN105524176B (zh) 2010-05-21 2011-05-20 双特异性融合蛋白

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US34704010P 2010-05-21 2010-05-21
US61/347,040 2010-05-21
PCT/US2011/037459 WO2011146902A1 (en) 2010-05-21 2011-05-20 Bi-specific fusion proteins
US13/112,907 US8691771B2 (en) 2010-05-21 2011-05-20 Bi-specific fusion proteins for tissue repair
US13/112,907 2011-05-20
US13/068,808 US9238080B2 (en) 2010-05-21 2011-05-20 Bi-specific fusion proteins
US13/068,808 2011-05-20

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201510960252.3A Division CN105524176B (zh) 2010-05-21 2011-05-20 双特异性融合蛋白

Publications (2)

Publication Number Publication Date
CN103124788A CN103124788A (zh) 2013-05-29
CN103124788B true CN103124788B (zh) 2016-01-13

Family

ID=44972647

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180035656.1A Active CN103124788B (zh) 2010-05-21 2011-05-20 双特异性融合蛋白

Country Status (9)

Country Link
US (11) US8691771B2 (enExample)
EP (1) EP2571992B1 (enExample)
JP (4) JP6200806B2 (enExample)
CN (1) CN103124788B (enExample)
AU (1) AU2011255238B2 (enExample)
BR (1) BR112012029611A2 (enExample)
CA (1) CA2800173C (enExample)
ES (1) ES2674567T3 (enExample)
WO (1) WO2011146902A1 (enExample)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5677972B2 (ja) * 2008-11-18 2015-02-25 メリマック ファーマシューティカルズ インコーポレーティッド ヒト血清アルブミンリンカーおよびそのコンジュゲート
CN102317315A (zh) 2009-02-11 2012-01-11 诺维信生物制药丹麦公司 白蛋白变体和缀合物
WO2011051489A2 (en) 2009-10-30 2011-05-05 Novozymes Biopharma Dk A/S Albumin variants
WO2011103076A1 (en) * 2010-02-16 2011-08-25 Medlmmune, Llc Hsa-related compositions and methods of use
US10233228B2 (en) 2010-04-09 2019-03-19 Albumedix Ltd Albumin derivatives and variants
EP2571992B1 (en) 2010-05-21 2018-04-25 Merrimack Pharmaceuticals, Inc. Bi-specific fusion proteins
US9045564B2 (en) 2011-02-15 2015-06-02 Medimmune, Llc HSA-related compositions and methods of use
US20140121163A1 (en) * 2011-04-28 2014-05-01 The Feinstein Institute for Medical Research a corporation Mfg-e8 and uses thereof
CN110272484A (zh) 2011-05-05 2019-09-24 阿尔布梅迪克斯医疗有限公司 白蛋白变体
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
HK1200842A1 (en) 2011-11-18 2015-08-14 Albumedix Ltd Proteins with improved half-life and other properties
ES2664328T3 (es) 2012-03-16 2018-04-19 Albumedix A/S Variantes de albúmina
US9289507B2 (en) 2012-05-17 2016-03-22 Extend Biosciences, Inc. Carriers for improved drug delivery
US9790264B2 (en) 2012-06-25 2017-10-17 The Brigham And Women's Hospital, Inc. Compounds and methods for modulating pharmacokinetics
DK2864360T3 (en) 2012-06-25 2017-12-18 Brigham & Womens Hospital Inc TARGETED THERAPY
US9345766B2 (en) 2012-08-30 2016-05-24 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-ERBB3 agents
EP2917233A1 (en) 2012-11-08 2015-09-16 Novozymes Biopharma DK A/S Albumin variants
CN105518143B (zh) * 2013-03-15 2020-02-21 北京凯得尔森生物技术有限公司 融合蛋白分子和它的使用方法
JP2017518965A (ja) 2014-05-02 2017-07-13 モメンタ ファーマシューティカルズ インコーポレイテッ エンジニアリングされたＦｃ構築物に関連する組成物および方法
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
US20170204149A1 (en) * 2014-06-23 2017-07-20 Novartis Ag Hsa-gdf-15 fusion polypeptide and use thereof
CN105273087A (zh) * 2014-07-14 2016-01-27 复旦大学 NGF-Fc融合蛋白及其制备方法
WO2016065042A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
EP3283068A1 (en) 2015-04-17 2018-02-21 Merrimack Pharmaceuticals, Inc. Combination treatments with seribantumab
CN104946656B (zh) * 2015-06-08 2018-08-17 吉林省农业科学院 一种人源碱性成纤维细胞生长因子、烟草叶绿体表达载体及生产方法
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
EA039859B1 (ru) * 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
JP7007261B2 (ja) 2015-08-20 2022-01-24 アルブミディクス リミティド アルブミン変異体及びコンジュゲート
GB2542391A (en) * 2015-09-17 2017-03-22 Annexin Pharmaceuticals Ab Process of manufacture
ES2863278T3 (es) * 2015-10-02 2021-10-11 Silver Creek Pharmaceuticals Inc Proteínas terapéuticas biespecíficas para la reparación de tejidos
EP3395366B1 (en) * 2015-12-21 2023-11-22 Hefei Lifeon Pharmaceutical Co., Ltd. Drug design method, obtained drug and application thereof
JP6904959B2 (ja) * 2016-01-04 2021-07-21 クール ファーマシューティカルズ ディベロップメント カンパニー インコーポレイテッド 結合エピトープを含有する融合タンパク質を封入する粒子
PL3411402T3 (pl) 2016-02-03 2022-02-28 Amgen Research (Munich) Gmbh Konstrukty bispecyficznych przeciwciał angażujących komórki T BCMA i CD3
WO2017134158A1 (en) 2016-02-03 2017-08-10 Amgen Research (Munich) Gmbh Psma and cd3 bispecific t cell engaging antibody constructs
EP3423572B1 (en) 2016-03-02 2023-11-29 Momenta Pharmaceuticals, Inc. Methods related to engineered fc constructs
KR20180119570A (ko) 2016-03-15 2018-11-02 메리맥 파마슈티컬즈, 인크. 항-ErbB3 항체를 포함하는 병용 요법을 이용한 ER+, HER2-, HRG+ 유방암의 치료
WO2017205436A1 (en) * 2016-05-23 2017-11-30 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc constructs
US11220531B2 (en) 2017-01-06 2022-01-11 Janssen Biotech, Inc. Engineered Fc constructs
EP3649147A4 (en) 2017-07-03 2021-04-14 Torque Therapeutics, Inc. POLYNUCLEOTIDES CODING IMMUNOSTIMULANT FUSION MOLECULES AND THEIR USES
JP7221545B2 (ja) * 2017-07-24 2023-02-14 ラトガース，ザ ステート ユニバーシティ オブ ニュー ジャージー ホスファチジルセリン標的化融合分子およびそれらの使用方法
CN113214410A (zh) * 2017-11-04 2021-08-06 海南大学 一种表达促皮质素与胰岛素样生长因子1融合蛋白的重组质粒、重组菌的构建方法
US11464803B2 (en) * 2017-11-14 2022-10-11 Arcellx, Inc. D-domain containing polypeptides and uses thereof
GB201919019D0 (en) * 2019-12-20 2020-02-05 Autolus Ltd Antigen-binding domain
EP4103609A1 (en) * 2020-02-13 2022-12-21 UCB Biopharma SRL Bispecific antibodies against cd9 and cd7
CN116917482A (zh) 2020-07-30 2023-10-20 银溪制药股份有限公司 嵌合蛋白和治疗中枢神经系统疾病的方法
CN115286713B (zh) * 2020-10-27 2024-07-23 温州医科大学 一种以结缔组织生长因子为靶点的全人源拮抗抗体及其应用
JP2023550895A (ja) * 2020-10-30 2023-12-06 セレメディー カンパニー，リミテッド 抗体様タンパク質およびその用途
US11946055B2 (en) * 2020-12-10 2024-04-02 The Regents Of The University Of California Protein engineering via error-prone orthogonal replication and yeast surface display
JP2024519578A (ja) * 2021-05-03 2024-05-17 セレメディー カンパニー，リミテッド 新規タンパク質
CN117659178B (zh) * 2022-08-23 2024-09-24 东莞市朋志生物科技有限公司 抗甲型流感病毒抗体或其功能性片段、检测甲型流感病毒的试剂和试剂盒
US12233115B2 (en) 2022-09-30 2025-02-25 Extend Biosciences, Inc. Long-acting parathyroid hormone
CN118420712A (zh) * 2023-02-01 2024-08-02 上海健信生物医药科技有限公司 一种三特异性抗体技术平台及其应用
CN116983407B (zh) * 2023-08-03 2025-10-28 艾可泰科(浙江)控股有限公司 一种治疗膝关节炎的新一代干细胞治疗剂及其制备工艺
CN117736344B (zh) * 2024-01-30 2024-06-21 南通大学 具有自组装性能的重复结构单元重组蛋白ⅡAⅡB-ⅡAⅡBrQTY及应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1564829A (zh) * 2001-01-05 2005-01-12 辉瑞大药厂 胰岛素样生长因子i受体的抗体
US20060275254A1 (en) * 2003-11-13 2006-12-07 Hanmi Pharm. Ind. Co., Ltd. Pharmaceutical composition comprising an immunoglobulin fc region as a carrier

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8819826D0 (en) 1988-08-20 1988-09-21 Kabivitrum Ab Glycosylated igf-1
US6541610B1 (en) * 1989-09-05 2003-04-01 Immunex Corporation Fusion proteins comprising tumor necrosis factor receptor
US5679771A (en) 1990-02-13 1997-10-21 Gropep Pty. Ltd. Method for treating intestinal diseases
US6566098B1 (en) 1990-09-14 2003-05-20 The United States Of America As Represented By The Department Of Health And Human Services DNA encoding truncated hepatocyte growth factor variants
EP0574395B1 (en) 1990-11-09 2002-06-12 GILLIES, Stephen D. Cytokine immunoconjugates
US5632986A (en) 1991-05-09 1997-05-27 The University Of Washington Phospholipid-targeted thrombolytic agents
AU7042994A (en) * 1993-05-21 1994-12-20 Amgen, Inc. Recombinant (neu) differentiation factors
CA2190752A1 (en) 1994-05-24 1995-11-30 George N. Cox Modified insulin-like growth factors
US5780052A (en) 1995-04-24 1998-07-14 Northeastern University Compositions and methods useful for inhibiting cell death and for delivering an agent into a cell
CA2224859A1 (en) 1996-04-17 1997-10-23 Amitabh Gaur Ligand inhibitors of insulin-like growth factor binding proteins and methods of use therefor
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
IL140700A0 (en) * 1998-07-13 2002-02-10 Univ Texas Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids
US6387663B1 (en) * 1998-07-31 2002-05-14 University Of Southern California Targeting pharmaceutical agents to injured tissues
AUPP785098A0 (en) 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
IL143834A0 (en) 1999-01-06 2002-04-21 Genentech Inc Insulin-like growth factor (igf) i mutant variants
US7087411B2 (en) * 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
EP1223953B1 (en) 1999-07-21 2006-02-01 University of Southern California Matrix-targeted fusion polypeptides for tissue regeneration and wound healing
GB2360771A (en) * 2000-03-28 2001-10-03 Antisoma Res Ltd Compounds for targeting
CA2419561A1 (en) 2000-08-29 2002-03-07 Colorado State University Research Foundation Method for treating the central nervous system by administration of igf structural analogs
US7635680B2 (en) * 2001-02-21 2009-12-22 Alavita Pharmaceuticals, Inc. Attenuation of reperfusion injury
IL158623A0 (en) 2001-04-30 2004-05-12 Symbiontics Inc Subcellular targeting of therapeutic proteins
US7049286B2 (en) * 2001-08-30 2006-05-23 Diatos, S.A. Insulin conjugates and methods of use thereof
AU2008200706B2 (en) 2001-10-16 2010-05-27 Biomarin Pharmaceutical Inc. Methods and compositions for targeting underglycosylated proteins across the blood brain barrier
US20030072761A1 (en) 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
WO2005077042A2 (en) * 2004-02-09 2005-08-25 Human Genome Sciences, Inc. Albumin fusion proteins
AU2003241313A1 (en) 2002-04-23 2003-11-10 Roger Williams Hospital Compositions and methods for stem cell delivery
CA2486362A1 (en) 2002-06-06 2003-12-18 Tze Chein Wun Novel recombinant anticoagulant proteins
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
US20040213738A1 (en) 2003-03-31 2004-10-28 Susan Croll-Kalish CIRL3-Like proteins, nucleic acids, and methods of modulating CIRL3-L-mediated activity
DE602004024195D1 (de) 2003-05-19 2009-12-31 Seikagaku Kogyo Co Ltd Sulfatgruppen-transferase-hemmer
US7355018B2 (en) 2003-09-30 2008-04-08 Regeneron Pharmaceuticals, Inc. Modified IGF1 polypeptides with increased stability and potency
AU2005203962C1 (en) * 2004-01-05 2012-11-08 Antisoma Research Limited Interleukin-12 targeted to oncofoetal fibronectin
EP1778270A4 (en) 2004-05-05 2009-09-02 Merrimack Pharmaceuticals Inc BIS-SPECIFIC BINDER FOR MODULATING BIOLOGICAL ACTIVITY
US20060018897A1 (en) 2004-06-28 2006-01-26 Transtarget Inc. Bispecific antibodies
US7511016B2 (en) * 2004-07-07 2009-03-31 Mosamedix B.V. Annexins, derivatives thereof, and annexin-cys variants, as well as therapeutic and diagnostic uses thereof
US7531318B2 (en) 2004-08-20 2009-05-12 Board Of Regents, The University Of Texas System Screening of agents for activity against ischemic myocardial insults
AU2005277094A1 (en) 2004-08-20 2006-03-02 Regenerx Biopharmaceuticals, Inc. Method of treating, preventing, inhibiting or reducing damage to cardiac tissue
CA2582552A1 (en) 2004-10-21 2006-05-04 Igf Oncology, Llc Toxins and radionuclides coupled to igf-1 receptor ligands for treatment of cancer
EP2289535B8 (en) * 2004-12-21 2018-08-08 MUSC Foundation for Research Development Compositions and methods for promoting wound healing and tissue regeneration
AU2006203882B2 (en) 2005-01-07 2011-05-12 Regeneron Pharmaceuticals, Inc. IGF-1 fusion polypeptides and therapeutic uses thereof
WO2006076525A2 (en) 2005-01-14 2006-07-20 Cytogen Corporation Combination cancer therapy with anti-psma antibodies
NZ556065A (en) 2005-01-24 2009-04-30 Univ Texas FC-fusion constructs binding to phosphatidylserine and their therapeutic use
BRPI0519897A2 (pt) 2005-02-23 2009-08-18 Merrimack Pharmaceuticals Inc método para modular a atividade ou atividades biológicas de moléculas alvo em uma célula alvo, agente de ligação biespecìfico, composição, uso de um agente de ligação biespecìfico, e, kit
US7521211B2 (en) * 2005-04-05 2009-04-21 Regeneron Pharmaceuticals, Inc IGF-1 and IGF-2 chimeric polypeptides and therapeutic uses thereof
CA2609728A1 (en) * 2005-05-27 2006-11-30 Five Prime Therapeutics, Inc. Methods of and compositions for stimulation of glucose uptake into muscle cells and treatment of diseases
MX2008001865A (es) 2005-08-12 2008-04-15 Human Genome Sciences Inc Proteinas de fusion de albumina.
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
WO2007044887A2 (en) 2005-10-11 2007-04-19 Transtarget, Inc. Method for producing a population of homogenous tetravalent bispecific antibodies
NZ569078A (en) 2005-12-12 2012-01-12 Mosamedix Bv Annexin derivatives suitable for pretargeting in therapy and diagnosis
US7776816B2 (en) 2006-01-20 2010-08-17 Board Of Regents, The University Of Texas System Preserving hypoxic tissue
KR20080098504A (ko) * 2006-02-03 2008-11-10 메디뮨 엘엘씨 단백질 제제
EA200870265A1 (ru) 2006-02-15 2009-02-27 Имклоун Системз Инкорпорейтед Функционально активные антитела
JP5374359B2 (ja) * 2006-03-17 2013-12-25 バイオジェン・アイデック・エムエイ・インコーポレイテッド 安定化されたポリペプチド化合物
US9187517B2 (en) 2006-11-13 2015-11-17 The Brigham And Women's Hospital, Inc. Methods of promoting cardiac repair using growth factors fused to heparin binding sequences
US8003761B2 (en) * 2007-01-23 2011-08-23 Hoffmann-La Roche Inc. Cancerous disease modifying antibodies
SE530073C2 (sv) 2007-01-23 2008-02-26 Teknikbolaget K Samuelsson Ab Sprutmunstycksanordning för brandsläckningssystem
WO2008124086A2 (en) 2007-04-05 2008-10-16 President And Fellows Of Harvard College Chimeric activators: quantitatively designed protein therapeutics and uses thereof
US20110045007A1 (en) 2007-05-31 2011-02-24 Genmab A/S Fusion or linked proteins with extended half life
WO2008151005A2 (en) 2007-05-31 2008-12-11 Transtarget, Inc. Compositions and methods for tissue repair
KR101631323B1 (ko) 2007-06-21 2016-06-17 엑스엘-프로테인 게엠베하 증가된 생체내 및/또는 시험관내 안정성을 갖는 생물학적 활성 단백질
WO2009030720A2 (en) 2007-09-06 2009-03-12 Novozymes Biopharma Dk A/S Process for producing a recombinant protein
JP5639039B2 (ja) 2008-04-11 2014-12-10 メリマック ファーマシューティカルズ インコーポレーティッド ヒト血清アルブミンリンカーおよびそのコンジュゲート
JP5677972B2 (ja) 2008-11-18 2015-02-25 メリマック ファーマシューティカルズ インコーポレーティッド ヒト血清アルブミンリンカーおよびそのコンジュゲート
CA2751068A1 (en) 2009-01-31 2010-08-05 Igf Oncology, Llc Anti-cancer protein-platinum conjugates
WO2011011071A2 (en) 2009-07-22 2011-01-27 Ipsen Pharma S.A.S. Analogues of insulin-like growth factor-1 (igf-1)
MX2012000757A (es) 2009-07-22 2012-08-03 Ipsen Pharma Sas Analogos de factor de crecimiento insulinoide tipo 1 (igf-1) que tienen sustitucion de aminoacidos en la posicion 59.
JP2013507926A (ja) 2009-10-14 2013-03-07 メリマック ファーマシューティカルズ インコーポレーティッド ＩＧＦ−１Ｒ及びＥｒｂＢ３シグナル伝達を標的とする二重特異的結合剤及びその使用
WO2011051489A2 (en) 2009-10-30 2011-05-05 Novozymes Biopharma Dk A/S Albumin variants
EP2571992B1 (en) * 2010-05-21 2018-04-25 Merrimack Pharmaceuticals, Inc. Bi-specific fusion proteins
AU2010365057B2 (en) 2010-12-08 2016-12-22 Viacyte, Inc. Agents and methods for inhibiting human pluripotent stem cell growth
HK1200842A1 (en) 2011-11-18 2015-08-14 Albumedix Ltd Proteins with improved half-life and other properties
CN109180802A (zh) 2011-12-15 2019-01-11 爱德迪安（北京）生物技术有限公司 具有降血糖作用的化合物、组合物及其用途
EP3395358B1 (en) 2012-09-26 2019-11-06 Indiana University Research and Technology Corporation Insulin analog dimers
KR20150134417A (ko) 2013-03-29 2015-12-01 메리맥 파마슈티컬즈, 인크. 연골-결합 융합 단백질
US9675671B2 (en) 2014-01-12 2017-06-13 Igf Oncology, Llc Fusion proteins containing insulin-like growth factor-1 and epidermal growth factor and variants thereof and uses thereof
ES2863278T3 (es) * 2015-10-02 2021-10-11 Silver Creek Pharmaceuticals Inc Proteínas terapéuticas biespecíficas para la reparación de tejidos
US11290711B2 (en) 2018-10-06 2022-03-29 Mediatek Inc. Method and apparatus of shared merge candidate list region for video coding

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1564829A (zh) * 2001-01-05 2005-01-12 辉瑞大药厂 胰岛素样生长因子i受体的抗体
US20060275254A1 (en) * 2003-11-13 2006-12-07 Hanmi Pharm. Ind. Co., Ltd. Pharmaceutical composition comprising an immunoglobulin fc region as a carrier

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Construction and characterization of a fusion protein with epidermal growth factor and the cell-binding domain of fibronectin;Kawase Y等;《FEBS Letters》;19920224;第298卷(第2-3期);126-128 *

Also Published As

Publication number Publication date
JP2017000143A (ja) 2017-01-05
AU2011255238B2 (en) 2015-06-04
US10407512B2 (en) 2019-09-10
US20210040233A1 (en) 2021-02-11
JP6174763B2 (ja) 2017-08-02
US8691771B2 (en) 2014-04-08
US20170335015A1 (en) 2017-11-23
US9238080B2 (en) 2016-01-19
US20230322951A1 (en) 2023-10-12
JP6200806B2 (ja) 2017-09-20
CN103124788A (zh) 2013-05-29
WO2011146902A1 (en) 2011-11-24
US9718892B2 (en) 2017-08-01
JP6965311B2 (ja) 2021-11-10
BR112012029611A2 (pt) 2017-07-25
JP6822911B2 (ja) 2021-01-27
US20110286976A1 (en) 2011-11-24
JP2013530146A (ja) 2013-07-25
JP2017225442A (ja) 2017-12-28
US20240101713A1 (en) 2024-03-28
CA2800173A1 (en) 2011-11-24
US11814443B2 (en) 2023-11-14
ES2674567T3 (es) 2018-07-02
US20140178380A1 (en) 2014-06-26
US20210214463A1 (en) 2021-07-15
EP2571992B1 (en) 2018-04-25
CA2800173C (en) 2019-05-14
US20160168269A1 (en) 2016-06-16
US10858450B2 (en) 2020-12-08
AU2011255238A1 (en) 2012-12-06
WO2011146902A9 (en) 2012-11-15
US10988547B2 (en) 2021-04-27
US20110293579A1 (en) 2011-12-01
US20180237540A1 (en) 2018-08-23
US9982060B2 (en) 2018-05-29
US11673970B2 (en) 2023-06-13
EP2571992A1 (en) 2013-03-27
US20200048368A1 (en) 2020-02-13
JP2019196365A (ja) 2019-11-14

Similar Documents

Publication Publication Date Title
US11814443B2 (en) Bi-specific fusion proteins
CN105524176B (zh) 双特异性融合蛋白
US12122819B2 (en) Method of treating skin tissue damage by topically administering a bi-specific protein comprising a human insulin-like growth factor variant and a human annexin A5 variant
AU2013202341A1 (en) Bi-specific fusion proteins

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20190730

Address after: American California

Patentee after: Silver brook pharmaceutical Limited by Share Ltd

Address before: Massachusetts, USA

Patentee before: Merrimack Pharmaceuticals Inc